Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.
|Articles|May 22, 1996
FDA says AMI agent is approvable
MRI contrast developer Advanced Magnetics of Cambridge, MA, hasscored its second approvable letter this year from the Food andDrug Administration. AMI announced this month that the agencyhas indicated that its Gastromark agent for MRI of the
Advertisement
MRI contrast developer Advanced Magnetics of Cambridge, MA, hasscored its second approvable letter this year from the Food andDrug Administration. AMI announced this month that the agencyhas indicated that its Gastromark agent for MRI of the gastrointestinaltract is approvable. The FDA issued a similar letter earlier thisyear for AMI's Feridex IV agent (SCAN 2/14/96).
Final FDA approval of Gastromark will trigger a milestone paymentto AMI from Mallinckrodt Medical, which has rights to the productin the U.S., Canada, and Mexico. Guerbet of France markets theproduct in Western Europe as Lumirem.
In other AMI news, the company has decided to take advantage ofthe recent drop in its stock price by authorizing a plan to buyback 250,000 of its 6.8 million shares outstanding.
Advertisement
Related to this article
For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.
The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Body Composition Analysis
2
Study Shows Impact of Key mpMRI Features for Enhancing Assessment of Renal Masses
3
Tumor Margin Marker on Contrast-Enhanced Ultrasound May Predict Worse Outcomes in Patients with HCC
4
Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia
5